Fig. 7: Synergy of Annexin A5-E7 fusion protein and immune checkpoint inhibitors.
From: Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment
C57BL/6 mice were injected with 2 × 105 TC-1 cells/mouse subcutaneously on day 0. Mice were then treated intraperitoneally with 5 mg/kg Cisplatin on days 15 and 18, intravenously with 200jig/mice of AnxA5-E7 proteins on days 16, 17, 19, and 20, and/or intraperitoneally with 200jig/mice of anti-PD-1, anti-PD-L1, or anti-TIM-3 antibodies on days 21, 23, and 25. The treatment groups are as follows: opened triangle - PBS only; opened circle - cisplatin only; opened square - cisplatin and Annexin 5A-E7; closed square – cisplatin, Annexin 5A-E7, and anti-PD-1; closed circle – cisplatin, Annexin 5A-E7, and anti-PD-L1; closed triangle - cisplatin, Annexin A5-E7, and anti-TIM3. a Schematic diagram. b Line graph depicting TC-1 tumor growth in different treatment groups over time (n = 10). P-values were determined by one-way ANOVA and Turkey’s test. c Kaplan–Meier survival analysis of TC-1 tumor-bearing mice in different treatment groups (n = 10), and the overall P-value was calculated by the log-rank test. d One week after the last AnxA5-E7 vaccination, spleens of TC-1 tumor-bearing mice in different treatment groups were harvested and analyzed for CD8+IFN-γ+ T cells by flow cytometry analysis. Figure showing representative flow cytometry analysis and bar graph depicting the abundance of CD8+IFN-γ+ T cells in splenocytes of TC-1 tumor-bearing mice in different treatment groups (n = 3). P-values were analyzed by Student’s t test. The error bars indicate mean ± SD. The results are representative of one of three independent experiments. Source data are provided as a Source Data file.
